SK chemicals said that it signed a co-marketing agreement with Jeil Health Science for select over-the-counter (OTC) products from the Ginexin and Trast product lines -- Ginexin-F Soft Cap. 120mg and Trast Patch 30.

Jeil Health Science and SK chemicals have partnered to co-promote the latter’s Ginexin (left) and Trast. (Credit: SK chemicals)
Jeil Health Science and SK chemicals have partnered to co-promote the latter’s Ginexin (left) and Trast. (Credit: SK chemicals)

Ginexin, a blood circulation enhancer made from ginkgo leaf extract, is available in a soft capsule format exclusively for pharmacies. Trust, a pain relief patch, comes in three packaging formats—7s, 10s, and 30s—with the 30s version designed for patients requiring repeated use.

Under the agreement, Jeil Health Science will take charge of sales and marketing for pharmacies, leveraging its extensive distribution network. Previously, these products were distributed through general pharmaceutical wholesalers. Jeil Health Science is a leading OTC pharmaceutical company in Korea, boasting a nationwide sales force and a direct pharmacy distribution network exceeding 12,000 locations.

SK chemicals anticipates that this collaboration will strengthen pharmacy sales of its flagship OTC products, Ginexin and Trast.

"With Jeil Health Science’s extensive experience in pain relief products like Kefentech and Jeil Cool Pap, along with its strong pharmacy network, we can now execute a more aggressive marketing strategy," SK chemicals Pharma Planning Office head Park Hyun-sun said. "Through close cooperation with Jeil Health Science, we will continue reinforcing Ginkgshin and Trust as leading brands in their respective markets."

Jeil Health Science CEO Han Sang-chul also said, "We are honored to collaborate with SK chemicals on the sales of Ginexin and Trast, both of which have earned long-standing trust in the blood circulation and pain relief segments.”

By leveraging Jeil’s powerful sales force, the company aims to enhance the market competitiveness of these products and expand treatment options for more patients, Han added.

Related articles

Copyright © KBR Unauthorized reproduction, redistribution prohibited